These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8775519)

  • 1. Funding of coronary angioplasty and coronary stenting in public hospitals.
    Harper RW
    Aust N Z J Med; 1996 Feb; 26(1):3-4. PubMed ID: 8775519
    [No Abstract]   [Full Text] [Related]  

  • 2. Funding of coronary angioplasty in public hospitals.
    Eccleston DS; Eisenberg MJ
    Aust N Z J Med; 1996 Jun; 26(3):430-1. PubMed ID: 8811228
    [No Abstract]   [Full Text] [Related]  

  • 3. Funding of coronary angioplasty in public hospitals.
    Batey RG
    Aust N Z J Med; 1996 Jun; 26(3):430. PubMed ID: 8811227
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective.
    Cohen DJ
    Am Heart J; 1999 May; 137(5):S133-7. PubMed ID: 10220616
    [No Abstract]   [Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: an industry perspective.
    Marshall PR
    Am Heart J; 1999 May; 137(5):S138-41. PubMed ID: 10220617
    [No Abstract]   [Full Text] [Related]  

  • 6. Should use of intracoronary stents during percutaneous revascularisation be restricted?
    Palmer N; Fort S; Starkey I; Shaw T; Northridge D
    Lancet; 1998 Feb; 351(9100):416-7. PubMed ID: 9482299
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: a health system perspective.
    Ahmad M
    Am Heart J; 1999 May; 137(5):S142-4. PubMed ID: 10220618
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.
    Cohen DJ; Breall JA; Ho KK; Kuntz RE; Goldman L; Baim DS; Weinstein MC
    Circulation; 1994 Apr; 89(4):1859-74. PubMed ID: 8149551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.
    Cohen DJ; Breall JA; Ho KK; Weintraub RM; Kuntz RE; Weinstein MC; Baim DS
    J Am Coll Cardiol; 1993 Oct; 22(4):1052-9. PubMed ID: 8409040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and long-term cost implications of coronary stenting.
    Peterson ED; Cowper PA; DeLong ER; Zidar JP; Stack RS; Mark DB
    J Am Coll Cardiol; 1999 May; 33(6):1610-8. PubMed ID: 10334432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators.
    Cohen DJ; Krumholz HM; Sukin CA; Ho KK; Siegrist RB; Cleman M; Heuser RR; Brinker JA; Moses JW; Savage MP
    Circulation; 1995 Nov; 92(9):2480-7. PubMed ID: 7586348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting coronary stents: faith and hope, but no charity.
    Knudtson ML
    CMAJ; 2007 Jan; 176(2):195-6. PubMed ID: 17179218
    [No Abstract]   [Full Text] [Related]  

  • 14. PCI and stable coronary heart disease--COURAGE to change our minds?
    Kakafika AI; Mikhailidis DP; Wierzbicki AS; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2007 Jul; 5(3):173-4. PubMed ID: 17627560
    [No Abstract]   [Full Text] [Related]  

  • 15. [Coronary angioplasty: use and cost].
    Bossi I; De Servi S; Bramucci E; Angoli L
    G Ital Cardiol; 1997 May; 27(5):489-94. PubMed ID: 9244756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI).
    Yock CA; Boothroyd DB; Owens DK; Winston C; Hlatky MA
    Am Heart J; 2000 Oct; 140(4):556-64. PubMed ID: 11011328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an aggressive stenting strategy on initial and one-year follow-up costs in patients undergoing coronary angioplasty.
    Farshid A; Leong B; Pitney M; McCredie RM; Allan R
    Aust N Z J Med; 1999 Apr; 29(2):243-8. PubMed ID: 10342025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
    Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
    Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs, charges and revenues of elective coronary angioplasty and stenting: the public versus the private system.
    Harper RW; Sampson KD; See PL; Kealey JL; Meredith IT
    Med J Aust; 2000 Sep; 173(6):296-300. PubMed ID: 11061398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.